Improving

Human Health

We invest in early-stage life-science companies with the potential to enhance human well-being and quality of life.

ABOUT US LET'S TALK

Continuing to

Grow & Invest

We are an evergreen fund that has a long-term investment perspective.

OUR APPROACH LET'S TALK

Focusing on the

Mid-Atlantic Region

We invest in life-science companies in the Mid-Atlantic region.

OUR CRITERIA LET'S TALK

Launching Successful

Companies

Our portfolio companies have attracted over $4.4 billion of external capital to support their growth.

OUR PORTFOLIO LET'S TALK

Latest News

All Accelerated Biosciences Acuity Pharmaceuticals Allevi Alteris Annovis Atalan Avid Radiopharmaceuticals Bainbridge Health BioAdvance News BobcatBio Ceptaris Cohero Health Concarlo Therapeutics CrossBridge Eliksa Therapeutics ENB Therapeutics General Halo Labs Hanimune Therapeutics HealthQx HueDx ImmunoGenesis Immunome InfraScan Innervace Intezyne iView Therapeutics KaloCyte Kayothera Keriton Latus LumenVu Mebias Discovery Melior Discovery Midway Pharmaceuticals Novira Therapeutics NuPathe Oncora Medical Onspira Therapeutics Opsidio Ossianix Palvella Therapeutics Phrase Health Pillo Health Portfolio News Protez Pharmaceuticals PST Relmada Therapeutics Renovacor Ride Health Senzo Strados The One Health Company Tolerance Bio Treventis Corporation Venatorx Pharmaceuticals Vesteck Vittoria Biotherapeutics Wellsheet

Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations

Latus Bio to Present New Data at ASGCT 2026 Supporting Investigational Gene Therapy Approaches for Huntington’s Disease and CLN2 Disease

Strados Labs Acquires Clinical Trial Business of NuvoAir, Delivering Full-Spectrum Respiratory Endpoint Solutions for Life Sciences

ImmunoGenesis Announces Poster Presentation at AACR 2026 Annual Meeting

Who We Are

OUR COMPANY

Who We Support

OUR PORTFOLIO